Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.73 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28346058 | 0.98 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL28300604 | 0.98 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL11567835 | 0.92 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL11074729 | 0.90 | CYP11B1 (0.61) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL14483736 | 0.85 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL31138008 | 0.85 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL4499181 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL10512975 | 0.84 | LMNA (0.62) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL2532397 | 0.83 | LMNA (0.78) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL28701756 | 0.81 | LMNA (0.75) | CYP11B1CYP11B2CYP1A2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994439-B | Preparation and application of hyaluronic acid-based composite polymer material | 杭州皓阳生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| CN-118994439-A | Preparation and application of hyaluronic acid-based composite polymer material | 杭州皓阳生物技术有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-117946203-A | Glycyrrhetinic acid-gold complex and preparation method and application thereof | 南京中医药大学 | 2024-04-30 | — | — | CN | claimed |
| CN-116589505-A | Cyano Fe with single-molecule magnet behavior III2 Co Ⅱ Complex, preparation method and application | 大连理工大学 | 2023-08-15 | — | — | CN | claimed |
| WO-2023032492-A1 | REACTION ACCELERATOR | ＥＮＥＯＳ株式会社 | 2023-03-09 | — | — | WO | claimed |
| CN-113512003-B | Preparation method of 4- (imidazole-1-yl) phenol | 上海瀚诺威生物科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-113512003-A | Preparation method of 4- (imidazole-1-yl) phenol | 上海瀚诺威生物科技有限公司 | 2021-10-19 | — | — | CN | claimed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | claimed |
| CN-106249545-B | It is a kind of can selfreparing photosensitive dry film solder mask | 杭州福斯特应用材料股份有限公司 | 2019-06-25 | — | — | CN | claimed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-0028410-B1 | USE OF THROMBOXANE-SYNTHETASE INHIBITING COMPOUNDS IN THE TREATMENT OF OBESITY AND THE LOWERING OF INSULIN LEVELS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-30 | — | — | EP | claimed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | claimed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | claimed |
| EP-0028410-A1 | Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-05-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | CYP11B1 2310/4885CYP11B2 2457/4885CYP1A2 1037/4885 |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | CYP11B1 2753/4885CYP11B2 2830/4885CYP1A2 3498/4885 |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CYP11B1 3080/4885CYP11B2 3608/4885CYP1A2 3203/4885 |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | MLX, LDHA, CA2 | CYP11B1 2753/4885CYP11B2 2830/4885CYP1A2 3498/4885 |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | CYP11B1 2956/4885CYP11B2 3172/4885CYP1A2 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.